Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact:




Investor contact:




...

Related Keywords

Spain ,United States ,China ,Belgium ,Beerse ,Region Flamande ,Chinese ,American ,Edmond Chan ,Jenni Mildon ,Ciltacabtagene Autoleucel ,European Commission Grants Conditional Approval ,Legend Biotech United States Inc ,Janssen Biotech Inc ,Drug Administration ,American Society Of Clinical Oncology ,European Commission ,Janssen Cilag International ,Chinese Company Legend Biotech To Develop Investigational ,American Cancer Society ,Committee For Orphan Medicinal Products ,Janssen Research Development ,Johnson Company ,Johnson ,European Union ,European Medicines Agency ,Exchange Commission ,Cilag International ,Area Lead Haematology ,Johnson Innovative ,New England Journal ,Professor Jes ,San Miguel ,Translational Medicine ,Universidad De Navarra ,Jordan Schecter ,Vice President ,Disease Area Leader ,Multiple Myeloma ,Orphan Medicinal Products ,Product Characteristics ,Janssen Biotech ,Legend Biotech United States ,Innovative Medicine ,Janssen Research ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Janssen Cilag Limited ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Cancer Information ,Refractory Multiple Myeloma ,Available Therapies ,Clinical Scenarios Encountered ,Study Comparing ,Versus Pomalidomide ,Participants With Relapsed ,Lenalidomide Refractory Multiple Myeloma ,Standard Care ,Lenalidomide Refractory Multiple ,Targeted Treatment Approved ,Refractory Multiple Myeloma Who Have Received ,Least One Prior Line ,Commission Grants Conditional Approval ,First Cell Therapy ,Refractory Multiple ,Clin Cancer Res ,Potential Uses ,Front Immunol ,Janssen Enters Worldwide Collaboration ,License Agreement ,Chinese Company Legend Biotech ,Develop Investigational ,Markets ,